Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure

Gidlöf, Olof LU (2021) In Frontiers in Physiology 12.
Abstract

The natriuretic peptide system (NPS) plays a fundamental role in maintaining cardiorenal homeostasis, and its potent filling pressure-regulated diuretic and vasodilatory effects constitute a beneficial compensatory mechanism in heart failure (HF). Leveraging the NPS for therapeutic benefit in HF has been the subject of intense investigation during the last three decades and has ultimately reached widespread clinical use in the form of angiotensin receptor-neprilysin inhibition (ARNi). NPS enhancement via ARNi confers beneficial effects on mortality and hospitalization in HF, but inhibition of neprilysin leads to the accumulation of a number of other vasoactive peptides in the circulation, often resulting in hypotension and raising... (More)

The natriuretic peptide system (NPS) plays a fundamental role in maintaining cardiorenal homeostasis, and its potent filling pressure-regulated diuretic and vasodilatory effects constitute a beneficial compensatory mechanism in heart failure (HF). Leveraging the NPS for therapeutic benefit in HF has been the subject of intense investigation during the last three decades and has ultimately reached widespread clinical use in the form of angiotensin receptor-neprilysin inhibition (ARNi). NPS enhancement via ARNi confers beneficial effects on mortality and hospitalization in HF, but inhibition of neprilysin leads to the accumulation of a number of other vasoactive peptides in the circulation, often resulting in hypotension and raising potential concerns over long-term adverse effects. Moreover, ARNi is less effective in the large group of HF patients with preserved ejection fraction. Alternative approaches for therapeutic augmentation of the NPS with increased specificity and efficacy are therefore warranted, and are now becoming feasible particularly with recent development of RNA therapeutics. In this review, the current state-of-the-art in terms of experimental and clinical strategies for NPS augmentation and their implementation will be reviewed and discussed.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
ARNI, epigenetics, gene therapy, heart failure, natriuretic peptide system, non-coding RNAs, RNAi
in
Frontiers in Physiology
volume
12
article number
650124
publisher
Frontiers Media S. A.
external identifiers
  • scopus:85118164593
  • pmid:34721050
ISSN
1664-042X
DOI
10.3389/fphys.2021.650124
language
English
LU publication?
yes
additional info
Funding Information: This author was supported by grants from the Swedish Heart-and Lungfoundation (20200532 and 20190409), the Crafoord Foundation, the Åke Wiberg Foundation, The Magnus Bergvall Foundation, and the Royal Physiographic Society and the Maggie Stephens Foundation. Publisher Copyright: © Copyright © 2021 Gidlöf.
id
420928b2-e01e-4020-8e6b-12efa41a9a26
date added to LUP
2021-11-23 15:09:00
date last changed
2024-06-15 21:24:05
@article{420928b2-e01e-4020-8e6b-12efa41a9a26,
  abstract     = {{<p>The natriuretic peptide system (NPS) plays a fundamental role in maintaining cardiorenal homeostasis, and its potent filling pressure-regulated diuretic and vasodilatory effects constitute a beneficial compensatory mechanism in heart failure (HF). Leveraging the NPS for therapeutic benefit in HF has been the subject of intense investigation during the last three decades and has ultimately reached widespread clinical use in the form of angiotensin receptor-neprilysin inhibition (ARNi). NPS enhancement via ARNi confers beneficial effects on mortality and hospitalization in HF, but inhibition of neprilysin leads to the accumulation of a number of other vasoactive peptides in the circulation, often resulting in hypotension and raising potential concerns over long-term adverse effects. Moreover, ARNi is less effective in the large group of HF patients with preserved ejection fraction. Alternative approaches for therapeutic augmentation of the NPS with increased specificity and efficacy are therefore warranted, and are now becoming feasible particularly with recent development of RNA therapeutics. In this review, the current state-of-the-art in terms of experimental and clinical strategies for NPS augmentation and their implementation will be reviewed and discussed.</p>}},
  author       = {{Gidlöf, Olof}},
  issn         = {{1664-042X}},
  keywords     = {{ARNI; epigenetics; gene therapy; heart failure; natriuretic peptide system; non-coding RNAs; RNAi}},
  language     = {{eng}},
  month        = {{10}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Physiology}},
  title        = {{Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure}},
  url          = {{http://dx.doi.org/10.3389/fphys.2021.650124}},
  doi          = {{10.3389/fphys.2021.650124}},
  volume       = {{12}},
  year         = {{2021}},
}